Floatz logo

Osilodrostat

Adrenal Gland Hyperfunction

Johns Hopkins UniversitySmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Adrenal Gland Hyperfunction cohort.

Asset / SponsorPhaseRating
Anakinra
University Hospital, Basel, Switzerland
Phase 3BB
Metyrapone
Mayo Clinic
Phase 2CCC
Daratumumab
M.D. Anderson Cancer Center
Phase 1CC
Edicotinib
M.D. Anderson Cancer Center
Phase 1C
Semaglutide
University of Texas Southwestern Medical Center
N/AD
Hydrocortisone
University of Minnesota
Phase 1NR

Same molecule, other indications

Osilodrostat is also rated in:

Cushing disease due to pituitary adenomaActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →